Patents Assigned to Roslin Institute (Edinburgh)
-
Patent number: 7514258Abstract: A method of reconstituting an animal embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more animals. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: November 3, 2005Date of Patent: April 7, 2009Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7432415Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: March 2, 2005Date of Patent: October 7, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7413865Abstract: A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or platelet cell lineages in the sample or an expression product thereof.Type: GrantFiled: July 1, 2005Date of Patent: August 19, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Michael Clinton, Gino Miele, Jean Catherine Manson
-
Patent number: 7361804Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 29, 2000Date of Patent: April 22, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7355094Abstract: A method of reconstituting an animal embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more animals. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: October 6, 2006Date of Patent: April 8, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7329796Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 3, 2004Date of Patent: February 12, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7326824Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: July 9, 2002Date of Patent: February 5, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7326825Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: October 6, 2006Date of Patent: February 5, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 7321075Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: September 5, 2002Date of Patent: January 22, 2008Assignee: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20070217999Abstract: The present invention provides a reporter system comprising a reporter gene encoding a reporter protein that is secretable from cells in which it produced or expressed either in vitro or in vivo and excretable in a body fluid from whole animals comprising such systems. The reporter system is useful for the detection of gene activation events or biochemical changes related to, or that occur, as a result of altered metabolic or disease status or toxicological stress in toxicological screening.Type: ApplicationFiled: September 23, 2004Publication date: September 20, 2007Applicant: Roslin Institute (Edinburgh)Inventors: Anthony Clark, Helen Clark, Charles Wolf, Christopher Whitelaw, Kenneth Brown, Simon Temperley
-
Patent number: 7265262Abstract: This disclosure provides a system for creating cloned cells and embryos that are genetically modified. Cells are treated to increase expression of telomerase and potentially extend replicative capacity. One or more genetic modifications is made to inactivate a gene or confer desirable features, growing and selecting the cells as needed. The modified nucleus can then be transferred to a suitable recipient cell, which can then be used to grow an embryo with the conferred attributes. This technology makes it possible to create embryos, animals and embryonic cell lines with multiple genetic modifications, including homozygously inactivated genes and gene substitutions.Type: GrantFiled: March 21, 2002Date of Patent: September 4, 2007Assignee: Roslin Institute (Edinburgh)Inventors: A. John Clark, Wei Cui, Chris Denning, Debbiao Zhao
-
Publication number: 20060160080Abstract: A method for the determination of the sex of an avian subject is provided which comprises analysis of a sample from said subject with a nucleic acid probe comprising an at least 6 base pair fragment from a Female Associated Factor (FAF) nucleic acid sequence, or with an antibody to a protein coded for by said sequences.Type: ApplicationFiled: August 13, 2003Publication date: July 20, 2006Applicant: Roslin Institute (Edinburgh)Inventor: Michael Clinton
-
Publication number: 20060105323Abstract: A system for the detection of gene activation events is provided which comprises a nucleic acid construct encoding a protein of the lipocalin protein family and a peptide tag in which the expression of the construct in a cell or in the cells of a transgenic animal demonstrates the activation of a gene or genes of interest, in which the protein expressed is secreted from the cell and in which detection of the peptide tag indicates expression of the construct.Type: ApplicationFiled: July 25, 2003Publication date: May 18, 2006Applicant: Roslin Institute (Edinburgh) Biosciences Ltd.Inventors: Christopher Whitelaw, Anthony Clark, Helen Clark, Wolf Charles Roland
-
Publication number: 20060051813Abstract: A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or platelet cell lineages in the sample or an expression product thereof.Type: ApplicationFiled: July 1, 2005Publication date: March 9, 2006Applicant: Roslin Institute (Edinburgh)Inventors: Michael Clinton, Gino Miele, Jean Manson
-
Patent number: 6962787Abstract: A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or platelet cell lineages in the sample or an expression product thereof.Type: GrantFiled: October 31, 2001Date of Patent: November 8, 2005Assignee: Roslin Institute (Edinburgh)Inventors: Michael Clinton, Gino Miele, Jean Catherine Manson
-
Patent number: 6921665Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. The differentiated cell populations produced are suitable for use in tissue regeneration and non-therapeutic applications such as drug screening.Type: GrantFiled: November 26, 2001Date of Patent: July 26, 2005Assignees: Roslin Institute (Edinburgh), Geron CorporationInventors: Jim McWhir, Joseph D. Gold, J. Michael Schiff
-
Publication number: 20030106081Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: September 5, 2002Publication date: June 5, 2003Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20030101468Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: July 9, 2002Publication date: May 29, 2003Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20030037352Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: October 11, 2001Publication date: February 20, 2003Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20020124277Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: November 21, 2001Publication date: September 5, 2002Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut